Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Over-expression of BCL-2 anti-apoptotic proteins is common in cancers, making them key therapeutic targets.
• Nasopharyngeal Carcinoma (NPC) is a cancer where these proteins are implicated.
• Targeting anti-apoptotic proteins offers a promising strategy for cancer treatment.

Purpose of the Study:

• To evaluate the sensitivity of NPC cell lines (HK1 and C666-1) to Maritoclax and ABT-263.
• To investigate the combined effects of Maritoclax and ABT-263 on NPC cells.
• To assess the development of resistance to these agents in 3D NPC spheroid models.

Main Methods:

• Utilized SYBR Green I assay for cell proliferation.
• Employed 3D NPC spheroids to mimic tumor microenvironment.
• Dose- and time-dependent analyses of drug effects were performed.

Main Results:

• Maritoclax repressed MCL-1, BCL-2, and BCL-XL in a dose- and time-dependent manner.
• Maritoclax demonstrated single-agent activity against NPC cell proliferation.
• Combination therapy with Maritoclax and ABT-263 showed synergistic effects in HK1 cells and 3D spheroids.
• NPC spheroids exhibited delayed resistance development to single-agent Maritoclax or combination therapy.

Conclusions:

• Maritoclax exhibits significant anti-cancer activity in NPC models.
• The combination of Maritoclax and ABT-263 presents a synergistic therapeutic approach for NPC.
• These findings suggest potential clinical utility of Maritoclax, alone or with BH3 mimetics, for NPC management.